Gerresheimer has significantly ramped up its glass and plastic production capacities in India. A new modern plant to produce high quality plastic containers and closures was built at
By Sachin Ravikumar BENGALURU (Reuters) - Indian drug vial maker Schott Kaisha is expecting annual vial sales for COVID-19 shots to more than triple a.
Read more about India s largest vial maker expects sales to triple on vaccine ramp up on Business Standard. Schott Kaisha is also in talks with Indian manufacturers of Russia s Sputnik V vaccine to supply millions of vials, but is yet to receive bulk orders
20 May 2021 - 9:41
Picture used for representation
Reuters
Bengaluru: Indian drug vial maker Schott Kaisha is expecting annual vial sales for COVID-19 shots to more than triple as vaccine production, including by one of its top customers Serum Institute, increases in response to a monster second wave of infections.
An Indo-German joint venture between specialty glass makers Schott AG and Kaisha, the company expects to sell 380 million vials for COVID-19 vaccines in 2021-22, up from 113 million a year earlier, Director Rishad Dadachanji said in an interview. The demand from our major customers has gone up two-fold, and is indicated to go up three-fold in the near future, Dadachanji said.
India s largest vial maker expects sales to triple on COVID-19 vaccine ramp-up
May 20, 2021 10:10 PM PHT
Reuters
Indian drug vial maker Schott Kaisha is expecting annual vial sales for COVID-19 shots to more than triple as vaccine production, including by one of its top customers Serum Institute, increases in response to a monster second wave of infections.
An Indo-German joint venture between specialty glass makers Schott AG and Kaisha, the company expects to sell 380 million vials for COVID-19 vaccines in 2021-2022, up from 113 million a year earlier, director Rishad Dadachanji said in an interview. The demand from our major customers has gone up twofold, and is indicated to go up threefold in the near future, Dadachanji said.